GenixPharmaceucticals Corporation (V:GENX) — Stock Price
GenixPharmaceucticals Corporation (V:GENX) is currently trading at CA$0.02 CAD, down 25.00% today. Over the past 52 weeks, shares have ranged between CA$0.02 and CA$0.04. This page tracks GenixPharmaceucticals Corporation's live share price on the V exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see GenixPharmaceucticals Corporation (GENX) total market value.
GenixPharmaceucticals Corporation (GENX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks GenixPharmaceucticals Corporation's daily closing share price and trading volume on the V exchange over the past year, giving a clear view of recent price momentum and liquidity.
GenixPharmaceucticals Corporation Income Statement — Revenue, Profit & Earnings by Year
GenixPharmaceucticals Corporation's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CA$0.00 | CA$4.05K | CA$12.35K | CA$0.00 | CA$0.00 |
| Cost of Revenue | CA$0.00 | CA$2.75K | CA$9.08K | CA$0.00 | — |
| Gross Profit | CA$0.00 | CA$1.30K | CA$3.26K | CA$0.00 | — |
| Research & Development | — | — | — | — | — |
| SG&A | CA$114.17K | CA$174.23K | CA$278.83K | CA$434.26K | CA$1.12 Million |
| Total Operating Expenses | CA$153.28K | CA$245.05K | CA$893.24K | CA$1.03 Million | CA$1.65 Million |
| Operating Income | CA$-153.28K | CA$-241.00K | CA$-880.89K | CA$-1.03 Million | CA$-1.65 Million |
| EBITDA | — | — | — | CA$-497.69K | CA$-1.11 Million |
| EBIT | — | — | — | CA$-998.43K | CA$-1.61 Million |
| Interest Expense | CA$172.14K | CA$119.90K | CA$50.98K | CA$12.13K | CA$3.51K |
| Income Before Tax | CA$-335.06K | CA$-73.20K | CA$-4.40 Million | CA$-1.07 Million | CA$-1.65 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | CA$-335.06K | CA$-73.20K | CA$-4.40 Million | CA$-1.07 Million | CA$-1.65 Million |
GenixPharmaceucticals Corporation Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes GenixPharmaceucticals Corporation's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CA$50.98K | CA$45.55K | CA$223.46K | CA$4.25 Million | CA$4.77 Million |
| Total Current Assets | CA$50.98K | CA$38.78K | CA$215.55K | CA$240.32K | CA$188.21K |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | CA$1.74K | CA$5.78K | CA$1.41K | CA$16.50K | CA$4.87K |
| Inventory | — | CA$0.00 | CA$159.11K | CA$171.32K | CA$4.83K |
| Property, Plant & Equipment | — | — | — | CA$3.73K | CA$32.43K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | CA$1.47 Million | CA$1.23 Million | CA$1.36 Million | CA$1.05 Million | CA$755.19K |
| Total Current Liabilities | CA$1.47 Million | CA$1.23 Million | CA$1.36 Million | CA$1.05 Million | CA$744.46K |
| Long-term Debt | — | — | — | — | — |
| Net Debt | CA$999.29K | CA$804.18K | CA$499.89K | CA$168.36K | — |
| Total Stockholder Equity | CA$-1.42 Million | CA$-1.18 Million | CA$-1.14 Million | CA$3.20 Million | CA$4.01 Million |
| Retained Earnings | CA$-12.54 Million | CA$-12.20 Million | CA$-12.13 Million | CA$-7.74 Million | CA$-6.66 Million |
GenixPharmaceucticals Corporation Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how GenixPharmaceucticals Corporation generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CA$-124.07K | CA$-187.34K | CA$-220.67K | CA$-219.58K | CA$-428.31K |
| Capital Expenditures | CA$0.00 | CA$0.00 | CA$0.00 | CA$3.34K | CA$0.00 |
| Free Cash Flow | CA$-124.07K | CA$-187.34K | CA$-220.67K | CA$-222.92K | CA$-428.31K |
| Investing Cash Flow | — | — | — | CA$-3.34K | CA$-3.34K |
| Financing Cash Flow | CA$156.18K | CA$187.19K | CA$223.04K | CA$93.37K | CA$-129.48K |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | CA$0.00 | CA$27.36K | CA$59.21K | CA$258.82K | CA$809.37K |
| Depreciation | CA$1.13K | CA$1.13K | CA$547.42K | CA$563.12K | CA$535.81K |
| Change in Cash | CA$32.11K | CA$-151.00 | CA$2.36K | CA$-129.55K | CA$-557.79K |
GenixPharmaceucticals Corporation Earnings History — EPS Actual vs. Analyst Estimates
Track GenixPharmaceucticals Corporation's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jun 25, 2026 | — | — | — |
| Feb 26, 2026 | — | — | — |
| Sep 18, 2025 | — | — | — |
| Apr 30, 2023 | 0.00 | — | — |
| Jan 31, 2023 | 0.00 | — | — |
| Oct 31, 2022 | 0.00 | — | — |
| Jul 31, 2022 | 0.00 | — | — |
| Apr 30, 2022 | 0.00 | — | — |